Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.
Palisade Bio, Inc. develops next-generation oral PDE4 inhibitor prodrugs for inflammatory and fibrotic diseases. Its lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed for targeted delivery and selective bioactivation in the ileum and colon, with clinical development focused on ulcerative colitis and Crohn’s disease.
Company news commonly covers PALI-2108 clinical and translational data, pharmacokinetic and biomarker findings, disease-conference presentations, clinical advisory activity and healthcare investor events. Updates also describe the company’s precision pharmacology strategy and the role of gut-targeted PDE4 inhibition in inflammatory bowel disease programs.
Leading BioSciences successfully completed its merger with Seneca Biopharma, establishing Palisade Bio, Inc., which will begin trading on Nasdaq under the ticker PALI on April 28, 2021. The merger is accompanied by a $20 million private placement led by Altium Capital, enhancing financial resources for trial advancements. Palisade Bio's lead asset, LB1148, shows promise in improving post-operative gastrointestinal function and has received Fast Track Designation from the FDA for pediatric applications. This positions Palisade for significant clinical milestones within the next 12 to 18 months.